Abbreviations & Acronyms ADT = androgen deprivation treatment BCR = biochemical recurrence bGS = biopsy Gleason score CI = confidence interval cT = clinical T stage CZ = central zone EPE = extraprostatic extension GS = Gleason score HR = hazard ratio IDC-P = intraductal carcinoma of the prostate iPSA = initial prostatespecific antigen LN = lymph node n = nodal metastases pLND = pelvic lymph node dissections PSA = prostate-specific antigen PZ = peripheral zone RM = resection margin RP = radical prostatectomy sv = seminal vesicle invasion TVC = total volume of cancer TZ = transition zone Objective: To identify risk factors of biochemical recurrence after radical prostatectomy in high-risk patients. Methods: A total of 191 high-risk prostate cancer patients according to the D'Amico classification treated with radical prostatectomy at a single institution between April 2000 and December 2013 were enrolled. The pathological evaluation including intraductal carcinoma of prostate was reassessed, and the clinical and pathological risk factors of biochemical recurrence were analyzed. Results: The median follow up after radical prostatectomy was 49 months. The 5-year biochemical recurrence-free survival rate after radical prostatectomy in high-risk prostate cancer patients was 41.6%. Initial prostate-specific antigen, pathological Gleason score, seminal vesicle invasion, extraprostatic extension and intraductal carcinoma of the prostate were significantly associated with biochemical recurrence-free survival. The 5-year biochemical recurrence-free survival rates in patients with zero, one, two and three of these risk factors were 92.9%, 70.7%, 38.3% and 28.8%, respectively. In patients with four or more factors, the biochemical recurrence-free survival rate was 6.1% after 18 months. Conclusions: In D'Amico high-risk patients treated with radical prostatectomy, risk factors for biochemical recurrence can be identified. Patients with fewer risk factors have longer biochemical recurrence-free survival, even among these high-risk cases.
Introduction
The D'Amico classification estimated by cT, iPSA and bGS predicts the risk of BCR after radical treatment for localized prostate cancer. 1, 2 The D'Amico classification is also useful for deciding therapeutic methods, such as RP and radiotherapy. However, it appears that patient background affects the outcome in patients treated with RP, because the BCR rate in high-risk prostate cancer according to the D'Amico classification differs among institutions. 3 Previous reports suggested that pathological factors including IDC-P are also useful for the prediction of BCR after RP. 3, 4 Therefore, to evaluate the risk of BCR after RP, it is important to examine clinical and pathological factors other than cT, iPSA and bGS, which are included in the D'Amico classification.
In the present study, we reassessed the pathological features of prostate cancer after RP in cases of high-risk cancer according to the D'Amico classification, and analyzed the correlation between the outcome and the risk factors.
Methods
The current study was undertaken with the approval and institutional oversight of our institutional ethics committee review board. A total of 191 high-risk prostate cancer patients among 585 prostate cancer patients diagnosed at a single institute between April 2000 and December 2013 were enrolled. The patients were observed for >6 months after RP without adjuvant or neoadjuvant hormone therapy. All patients underwent antegrade radical retropubic prostatectomies with localized pLND, under a senior surgeon. Patients did not undergo nerve-sparing procedures for extended prostatectomies. Postoperative PSA levels were measured every 3 months after RP, and BCR was defined as a postoperative PSA level of ≥0.2 ng/mL.
We evaluated four clinical factors, iPSA, cT, bGS and the number of high-risk factors in the D'Amico classification, and eight pathological factors, pGS, n, sv, EPE, presence of positive RM, IDC-P, zonal origin of cancer focus (PZ/CZ or TZ), and TVC. The clinical and pathological factors were described by the Prostate Cancer Handling Agreement, 4th Edition and were reassessed for the present study. All pathological specimens were reviewed by a pathologist in the institution. IDC-P was defined as atypical epithelium occupying >50% of the acinar and conduit of the prostate including basal cells, and a dense cribriform or solid pattern existing in the foci on prostate specimens, which were evaluated as cancer foci of IDC-P. 5 TVC was measured based on Partin's report. 6 Recurrence period was defined as the time from the operation to the day of BCR or to the death date in fatal cases without BCR. In addition, surviving cases without BCR were evaluated as censored, and it was set as the withdrawal date on the follow-up period. BCR-free survival curves were generated by the Kaplan-Meier method and evaluated by the log-rank test. Univariate analysis of time to recurrence for cT, iPSA, bGS, number of high-risk factors in D'Amico classification, pT, sv, EPE, RM, IDC-P, TVC and zonal origin of cancer focus was analyzed by the Cox proportional hazards regression model. Multivariate analysis of the time to recurrence for cT, iPSA, pGS, sv, EPE, RM, IDC-P and TVC was incorporated by forward-stepwise Cox proportional hazards regression models. The number of risk factors by D'Amico classification and pT stage were excluded from explanatory variables for correlation in multivariate analysis because iPSA and cT influence the number of risk factors by D'Amico classification, whereas sv and EPE correlate with pT stage. Data were analyzed using JMP Pro version 11.2 software (SAS Institute, Cary, NC, USA). A value of P < 0.05 (two-sided) was considered to show statistical significance.
Results
The age range of all patients was 41-78 years (median 70 years), the follow-up period was 6-164 months (median 49 months) and the period to BCR was 0-131 months (median 19 months). Of the 191 patients, 20 (10.5%) had PSA levels that did not decline to <0.2 ng/mL. The patients' characteristics are shown in Table 1 . The number of patients with stage pT3a and pT3b was 77 (40.3%) and 36 (18.9%), respectively. Among patients diagnosed as localized cancer by preoperative evaluation, 59.2% had locally advanced prostate cancer. Nodal metastases were detected in four patients (2%). The number of patients with positive RM was 91 (47.6%). Although 141 patients (73.8%) were preoperatively diagnosed as high-risk cancer with bGS ≥8, just 74 patients had pGS ≥8 after RP (38.7%).
The BCR-free survival curves of high-risk cancer categorized by D'Amico classification are shown in Figure 1 . The 5-year BCR-free survival rate after RP was 41.6% in all high-risk patients. The 5-year BCR-free survival rate of patients with one (n = 134, 70.1%) or two (n = 42, 22.0%) risk factors was 50% and 27%, respectively. In patients with three risk factors (n = 15, 7.9%), the BCR-free survival rate was 18.4% at 1 year and 0% after 13 months. The poor prognosis of high-risk cancer patients depended on the number of risk factors, such as high iPSA (>20 ng/mL), high bGS (≥8) and high cT (≥cT2c).
In the univariate analysis, iPSA (P = 0.0304), pGS (P = 0.0017) and IDC-P (P < 0.0001) were significantly associated with BCR-free survival. According to multivariate analysis, iPSA (≥10 vs <10: HR 1.90, 95% CI 1.13-3.24, P = 0.0148), pGS (≥8 vs <8: HR 1.90, 95% CI 1.25-2.9, P = 0.0028), sv (1 vs 0: HR 1.76, 95% CI 1.05-2.88, P = 0.0309), EPE (1, X vs 0: HR 2.02, 95% CI 1.14-3.70, P = 0.0153) and IDC-P (positive vs negative: HR 2.39, 95% CI 1.54-3.72, P < 0.0001) were all found to be significantly associated with BCR-free survival (Table 2) .
These five factors are considered to be significant independent factors for predicting the risk of BCR, and the BCR-free survival curves of the patients stratified by these predictive factors are shown in Figure 2 . The 5-year BCR-free survival rate in patients with zero (n = 19, 10.0%), one (n = 34, 17.8%), two (n = 65, 34.0%) or three (n = 33, 17.3%) risk factors was 92.9%, 70.7%, 38.3% and 28.8%, respectively. In patients with four or more factors (n = 40, 20.9%), the BCRfree survival rate was 24.3% at 1 year and 6.1% after 18 months.
Discussion
Approximately 15-25% of cases of localized prostate cancer are classified as high-risk prostate cancer by the D'Amico classification, and the 10-year cancer-specific survival rate of these patients who undergo RP is 85-90%. 7 Previous reports showed that the rate of 5-year BCR-free survival for patients with EPE, sv or RM was 30-60%. 2, 8 In the present study, the 5-year BCR-free survival rate after RP was 41.6% in high-risk patients; this result was similar to previous reports of BCR-free survival after RP. 3 However, even though the patients were diagnosed as high-risk prostate cancer by the D'Amico classification, 10% of them were iPSA ≤10 ng/mL, pGS <8, sv (À), EPE (À) and IDC-P (À). The 5-year BCRfree survival rate among these patients was 92.9%, and the possibility of BCR was extremely low. Incongruities between cT and pT stages, and between bGS and pGS might have led to an underestimation of some patients' risk factors. In the present study, 74.3% (84/113) of the cT2 patients were upgraded to pT3. Incongruity between clinical and pathological T stage is plausible, because cases that are preoperatively evaluated as clinical stage cT1 might be later found to be at a pathological stage of T2 or more. For biopsy GS compared with GS found at postoperative pathology evaluation, the percentages of upgraded and downgraded GS scores were 12% (23/191) and 42% (80/191), respectively (data not shown). Incongruity between preoperative and postoperative factors, such as T stage or GS, might complicate the exact prediction of recurrence according to preoperative factors. To predict each patient's survival more accurately, we should re-evaluate the predictive factors, including postoperative factors. Previous reports showed that preoperative factors (e.g. iPSA, cT, bGS, number of high-risk factors in the D'Amico classification, PSA velocity, PSA density, number of positive cancers in biopsy or the number of cancer foci in biopsy specimens) 1,9-11 and pathological factors (e.g. pGS, n, sv, EPE, RM or TVC) 12 were predictive factors for BCR and cancer mortality. bGS was not a risk factor of BCR in the present study, possibly because cancer estimation by bGS might not correspond to the real cancer situation. Although the estimation methods of bGS include the highest Gleason grading system, re-evaluation of the Gleason grading system for the biopsy specimen might be necessary for its use as a predictive factor when deciding treatment methods.
Recent reports showed that IDC-P was useful as a predictive factor of BCR and patient survival. 4 IDC-P involves expansive proliferation of malignant secretory cells within pre-existing prostatic ducts and acini, and often exists in tumors with a large volume or in invasive carcinoma of Gleason score 4 and 5. Although IDC-P is generally defined as a cribriform carcinoma with respect to its basal cells, which preserve the form of prostatic ducts and acini, the distinction between IDC-P and cribriform high-grade prostatic intraepithelial neoplasia is equivocal because of the differing definitions proposed by some reports. MacNeal et al. have suggested that the definition of IDC-P includes a solid or dense cribriform pattern and/or a micropapillary/loose cribriform pattern with a low nuclear grade. [13] [14] [15] Ebstein et al. have defined IDC-P as malignant epithelial cells filling >50% of large acini and prostatic ducts, with preservation of basal cells forming either solid/dense cribriform patterns, or loose cribriform/micropapillary patterns with either marked nuclear atypia (nuclear size ≥6-fold normal) or comedonecrosis. 16, 17 The latter definition was adapted in the 2016 revision to the World Health Organization classification, and is strict for diagnosis of IDC-P, because it is based on evaluation of prostate tissue biopsy samples. In the present study, we evaluated whole tissues excised by radical prostatectomy; none of the cases had only loose cribriform/micropapillary patterns with either marked nuclear atypia or comedonecrosis. To apply this to previous reports, we adopted a definition: atypical epithelial cells that fill >50% of large acini and prostatic ducts, with preserved basal cells forming a solid/dense cribriform pattern. Patients with IDC-P have a high risk of recurrence after RP, radiotherapy and hormone therapy. 14, 18 In the present study, IDC-P was the highest risk factor for BCR after RP (HR 2.39) compared with other factors. In patients with IDC-P in biopsy specimens, we should pay close attention to progression of cancer due to delayed treatment during active surveillance. To improve BCR in patients with high-risk prostate cancer, some reports suggested methods such as extended dissection of the prostate and extended pLND during RP, and adjuvant radiotherapy or hormone therapy after RP. [19] [20] [21] Because RP for high-risk prostate cancer tends to cause positive RM, extended dissection of the prostate reduces the risk of RM. 22, 23 Regarding LN metastasis of prostate cancer, the percentage of positive LNs was 5-7% in cases of localized pLND, and 15-30% in cases of extended pLND. The guideline recommends extended pLND for accurate staging to decide the postoperative treatment strategy in LN-positive cases. 24 In the present study, we carried out localized pLND in all cases, and just four patients (2%) had LN metastasis. The cases with LN metastasis were excluded from analysis of predictive factors of BCR. We need to assess the risk factors in cases of extended pLND, because there must be patients with advanced cancer with LN metastasis in our series.
Some reports showed that adjuvant radiation therapy after RP improved BCR, the appearance of distant metastasis and overall survival at doses of 60-64 Gy in pT3 cases, [25] [26] [27] but might have a detrimental effect in elderly patients aged ≥70 years. 25 These results suggested that postoperative adjuvant radiation therapy is recommended for pT3N0M0 patients, in particular cases with sv with a life expectancy of >15 years. However, Schild et al. reported that salvage radiation therapy after BCR has no efficacy for improvement of patient survival. 28 There is still no definite conclusion about the role of adjuvant radiation therapy after RP.
In some reports of adjuvant hormone therapy in pN1 cases, early ADT prolonged progression-free, disease-specific and overall survival, and adjuvant RT with early ADT improved long-term outcomes compared with early ADT alone. 29 However, Wong et al. showed that early ADT in pN1 patients might not significantly compromise survival. 30 There are also controversial opinions about patient survival with and without immediate hormone therapy. According to the National Comprehensive Cancer Network clinical practice guideline, adjuvant hormone therapy, RT and follow-up observation for pN1 cases after RP are included in category 1, 2B and 2B, respectively. However, follow-up observation is recommended until detectable PSA in patients without LN metastasis. Because BCR-free survival of patients in the present study with four or five risk factors after RP was very short, we should confirm the need for early adjuvant therapy after RP.
Although the present study is meaningful for predicting BCR of high-risk prostate cancer after RP, it had some limitations. First, it was a retrospective study, and we did not carry out validation for our results. Second, we did not evaluate other factors, such as PSA velocity, PSA density and free/total PSA ratio, that might influence BCR. Third, our patients did not undergo extensive RP and extensive pLND.
In summary, we identified the risk factors of BCR in highrisk patients treated with RP, and categorized patient outcome according to the number of risk factors. Patients who had few of these risk factors, including high iPSA, high pGS, presence of sv, presence of EPE and positive IDC-P, have long BCR-free survival even though they were classified as D'Amico high-risk patients. These results provide important information for predicting BCR after RP.
